fb 777 casino

fb 777 casino LOS ANGELES (AP) — Hannah Hidalgo scored 24 points and No. 6 Notre Dame defeated JuJu Watkins and third-ranked Southern California 74-61 on Saturday in a marquee matchup on the West Coast. Watkins and the Trojans (4-1) fell behind early and were down 21 points in the fourth quarter. She had 24 points, six rebounds and five assists. Hidalgo came out shooting well, hitting 5 of 8 from the floor in the first quarter and had 16 points at the break. She added six rebounds and eight assists. Hidalgo's backcourt mate, Olivia Miles, added 20 points, eight rebounds and seven assists for the Fighting Irish (5-0). Even though Hidalgo outshone her, Watkins’ imprint was all over the game. A documentary about her life aired on NBC leading into the nationally televised game. A buzz arose when Snoop Dogg walked in shortly before tipoff wearing a jacket in USC colors with Watkins' name and number on the front and back. Her sister, Mali, sang the national anthem. Notre Dame: The Irish struck quickly, racing to a 20-10 lead in the opening quarter. Even after cooling off a bit, they never trailed and stayed poised when the Trojans got within three in the second and third quarters. USC: The Trojans were without starting guard Kennedy Smith, whose defense on Hidalgo would have proven valuable. It was announced shortly before tipoff that she had a surgical procedure and will return at some point this season. The Trojans got within three points three times but the Irish remained poised and never gave up the lead. Notre Dame's defense forced the Trojans into 21 turnovers, which led to 22 points for the Irish. Watkins, Kaleigh Heckel and Talia von Oelhoffen had five each. USC was just 1 of 13 from 3-point range Notre Dame plays TCU on Nov. 29 in the Cayman Islands Classic. USC plays Seton Hall in the Women's Acrisure Holiday Invitational on Nov. 27 in Palm Desert, California. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here. AP women’s college basketball: https://apnews.com/hub/ap-top-25-womens-college-basketball-poll and https://apnews.com/hub/womens-college-basketball

CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $Revolutionizing Warehouse Operations: The Smart Solutions of Lyric

It was no different for Jimmy Carter in the early 1970s. It took meeting several presidential candidates and then encouragement from an esteemed elder statesman before the young governor, who had never met a president himself, saw himself as something bigger. He announced his White House bid on December 12 1974, amid fallout from the Vietnam War and the resignation of Richard Nixon. Then he leveraged his unknown, and politically untainted, status to become the 39th president. That whirlwind path has been a model, explicit and otherwise, for would-be contenders ever since. “Jimmy Carter’s example absolutely created a 50-year window of people saying, ‘Why not me?’” said Steve Schale, who worked on President Barack Obama’s campaigns and is a long-time supporter of President Joe Biden. Mr Carter’s journey to high office began in Plains, Georgia where he received end-of-life care decades after serving as president. David Axelrod, who helped to engineer Mr Obama’s four-year ascent from state senator to the Oval Office, said Mr Carter’s model is about more than how his grassroots strategy turned the Iowa caucuses and New Hampshire primary into his springboard. “There was a moral stain on the country, and this was a guy of deep faith,” Mr Axelrod said. “He seemed like a fresh start, and I think he understood that he could offer something different that might be able to meet the moment.” Donna Brazile, who managed Democrat Al Gore’s 2000 presidential campaign, got her start on Mr Carter’s two national campaigns. “In 1976, it was just Jimmy Carter’s time,” she said. Of course, the seeds of his presidential run sprouted even before Mr Nixon won a second term and certainly before his resignation in August 1974. In Mr Carter’s telling, he did not run for governor in 1966, he lost, or in 1970 thinking about Washington. Even when he announced his presidential bid, neither he nor those closest to him were completely confident. “President of what?” his mother, Lillian, replied when he told her his plans. But soon after he became governor in 1971, Mr Carter’s team envisioned him as a national player. They were encouraged in part by the May 31 Time magazine cover depicting Mr Carter alongside the headline “Dixie Whistles a Different Tune”. Inside, a flattering profile framed Mr Carter as a model “New South” governor. In October 1971, Carter ally Dr Peter Bourne, an Atlanta physician who would become US drug tsar, sent his politician friend an unsolicited memo outlining how he could be elected president. On October 17, a wider circle of advisers sat with Mr Carter at the Governor’s Mansion to discuss it. Mr Carter, then 47, wore blue jeans and a T-shirt, according to biographer Jonathan Alter. The team, including Mr Carter’s wife Rosalynn, who died aged 96 in November 2023, began considering the idea seriously. “We never used the word ‘president’,” Mr Carter recalled upon his 90th birthday, “but just referred to national office”. Mr Carter invited high-profile Democrats and Washington players who were running or considering running in 1972, to one-on-one meetings at the mansion. He jumped at the chance to lead the Democratic National Committee’s national campaign that year. The position allowed him to travel the country helping candidates up and down the ballot. Along the way, he was among the Southern governors who angled to be George McGovern’s running mate. Mr Alter said Mr Carter was never seriously considered. Still, Mr Carter got to know, among others, former vice president Hubert Humphrey and senators Henry Jackson of Washington, Eugene McCarthy of Maine and Mr McGovern of South Dakota, the eventual nominee who lost a landslide to Mr Nixon. Mr Carter later explained he had previously defined the nation’s highest office by its occupants immortalised by monuments. “For the first time,” Mr Carter told The New York Times, “I started comparing my own experiences and knowledge of government with the candidates, not against ‘the presidency’ and not against Thomas Jefferson and George Washington. It made it a whole lot easier”. Adviser Hamilton Jordan crafted a detailed campaign plan calling for matching Mr Carter’s outsider, good-government credentials to voters’ general disillusionment, even before Watergate. But the team still spoke and wrote in code, as if the “higher office” were not obvious. It was reported during his campaign that Mr Carter told family members around Christmas 1972 that he would run in 1976. Mr Carter later wrote in a memoir that a visit from former secretary of state Dean Rusk in early 1973 affirmed his leanings. During another private confab in Atlanta, Mr Rusk told Mr Carter plainly: “Governor, I think you should run for president in 1976.” That, Mr Carter wrote, “removed our remaining doubts.” Mr Schale said the process is not always so involved. “These are intensely competitive people already,” he said of governors, senators and others in high office. “If you’re wired in that capacity, it’s hard to step away from it.” “Jimmy Carter showed us that you can go from a no-name to president in the span of 18 or 24 months,” said Jared Leopold, a top aide in Washington governor Jay Inslee’s unsuccessful bid for Democrats’ 2020 nomination. “For people deciding whether to get in, it’s a real inspiration,” Mr Leopold continued, “and that’s a real success of American democracy”.Mike Tyson to 'enter ring' again in 2025 as official announcement madeThe Wildcats (8-4, 6-2 Coastal Athletic Association) spotted Maine to a 9-0 lead when Joey Bryson kicked a 39-yard field and Carter Peevy threw an 8-yard touchdown to Montigo Moss, all in the first quarter. But midway through the second, the Wildcats took control and proceeded to score 27-straight points to clinch the win. Denzell Gibson ran it in from the 1 to end a 13-play, 81-yard drive that lasted 6:08 to reduce the deficit to 9-7 with 11 seconds left before halftime. On the first play from scrimmage after the break, Mead ran for a 57-yard touchdown for a 14-9 lead. Nick Mazzie kicked field goals of 21 and 22 yards and Seth Morgan ran it in from the 7 with 2:03 left to end it. Peevy threw for 168 yards for Maine (5-7, 3-5). ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP collegebasketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball

WASHINGTON (AP) — As a former and potentially future president, Donald Trump hailed what would become Project 2025 as a road map for “exactly what our movement will do” with another crack at the White House. As the blueprint for a hard-right turn in America became a liability during the 2024 campaign, Trump pulled an about-face . He denied knowing anything about the “ridiculous and abysmal” plans written in part by his first-term aides and allies. Now, after being elected the 47th president on Nov. 5, Trump is stocking his second administration with key players in the detailed effort he temporarily shunned. Most notably, Trump has tapped Russell Vought for an encore as director of the Office of Management and Budget; Tom Homan, his former immigration chief, as “border czar;” and immigration hardliner Stephen Miller as deputy chief of policy . Those moves have accelerated criticisms from Democrats who warn that Trump's election hands government reins to movement conservatives who spent years envisioning how to concentrate power in the West Wing and impose a starkly rightward shift across the U.S. government and society. Trump and his aides maintain that he won a mandate to overhaul Washington. But they maintain the specifics are his alone. “President Trump never had anything to do with Project 2025,” said Trump spokeswoman Karoline Leavitt in a statement. “All of President Trumps' Cabinet nominees and appointments are whole-heartedly committed to President Trump's agenda, not the agenda of outside groups.” Here is a look at what some of Trump's choices portend for his second presidency. The Office of Management and Budget director, a role Vought held under Trump previously and requires Senate confirmation, prepares a president's proposed budget and is generally responsible for implementing the administration's agenda across agencies. The job is influential but Vought made clear as author of a Project 2025 chapter on presidential authority that he wants the post to wield more direct power. “The Director must view his job as the best, most comprehensive approximation of the President’s mind,” Vought wrote. The OMB, he wrote, “is a President’s air-traffic control system” and should be “involved in all aspects of the White House policy process,” becoming “powerful enough to override implementing agencies’ bureaucracies.” Trump did not go into such details when naming Vought but implicitly endorsed aggressive action. Vought, the president-elect said, “knows exactly how to dismantle the Deep State” — Trump’s catch-all for federal bureaucracy — and would help “restore fiscal sanity.” In June, speaking on former Trump aide Steve Bannon’s “War Room” podcast, Vought relished the potential tension: “We’re not going to save our country without a little confrontation.” The strategy of further concentrating federal authority in the presidency permeates Project 2025's and Trump's campaign proposals. Vought's vision is especially striking when paired with Trump's proposals to dramatically expand the president's control over federal workers and government purse strings — ideas intertwined with the president-elect tapping mega-billionaire Elon Musk and venture capitalist Vivek Ramaswamy to lead a “Department of Government Efficiency.” Trump in his first term sought to remake the federal civil service by reclassifying tens of thousands of federal civil service workers — who have job protection through changes in administration — as political appointees, making them easier to fire and replace with loyalists. Currently, only about 4,000 of the federal government's roughly 2 million workers are political appointees. President Joe Biden rescinded Trump's changes. Trump can now reinstate them. Meanwhile, Musk's and Ramaswamy's sweeping “efficiency” mandates from Trump could turn on an old, defunct constitutional theory that the president — not Congress — is the real gatekeeper of federal spending. In his “Agenda 47,” Trump endorsed so-called “impoundment,” which holds that when lawmakers pass appropriations bills, they simply set a spending ceiling, but not a floor. The president, the theory holds, can simply decide not to spend money on anything he deems unnecessary. Vought did not venture into impoundment in his Project 2025 chapter. But, he wrote, “The President should use every possible tool to propose and impose fiscal discipline on the federal government. Anything short of that would constitute abject failure.” Trump's choice immediately sparked backlash. “Russ Vought is a far-right ideologue who has tried to break the law to give President Trump unilateral authority he does not possess to override the spending decisions of Congress (and) who has and will again fight to give Trump the ability to summarily fire tens of thousands of civil servants,” said Sen. Patty Murray of Washington, a Democrat and outgoing Senate Appropriations chairwoman. Reps. Jamie Raskin of Maryland and Melanie Stansbury of New Mexico, leading Democrats on the House Committee on Oversight and Accountability, said Vought wants to “dismantle the expert federal workforce” to the detriment of Americans who depend on everything from veterans' health care to Social Security benefits. “Pain itself is the agenda,” they said. Trump’s protests about Project 2025 always glossed over overlaps in the two agendas . Both want to reimpose Trump-era immigration limits. Project 2025 includes a litany of detailed proposals for various U.S. immigration statutes, executive branch rules and agreements with other countries — reducing the number of refugees, work visa recipients and asylum seekers, for example. Miller is one of Trump's longest-serving advisers and architect of his immigration ideas, including his promise of the largest deportation force in U.S. history. As deputy policy chief, which is not subject to Senate confirmation, Miller would remain in Trump's West Wing inner circle. “America is for Americans and Americans only,” Miller said at Trump’s Madison Square Garden rally on Oct. 27. “America First Legal,” Miller’s organization founded as an ideological counter to the American Civil Liberties Union, was listed as an advisory group to Project 2025 until Miller asked that the name be removed because of negative attention. Homan, a Project 2025 named contributor, was an acting U.S. Immigration and Customs Enforcement director during Trump’s first presidency, playing a key role in what became known as Trump's “family separation policy.” Previewing Trump 2.0 earlier this year, Homan said: “No one’s off the table. If you’re here illegally, you better be looking over your shoulder.” John Ratcliffe, Trump's pick to lead the CIA , was previously one of Trump's directors of national intelligence. He is a Project 2025 contributor. The document's chapter on U.S. intelligence was written by Dustin Carmack, Ratcliffe's chief of staff in the first Trump administration. Reflecting Ratcliffe's and Trump's approach, Carmack declared the intelligence establishment too cautious. Ratcliffe, like the chapter attributed to Carmack, is hawkish toward China. Throughout the Project 2025 document, Beijing is framed as a U.S. adversary that cannot be trusted. Brendan Carr, the senior Republican on the Federal Communications Commission, wrote Project 2025's FCC chapter and is now Trump's pick to chair the panel. Carr wrote that the FCC chairman “is empowered with significant authority that is not shared” with other FCC members. He called for the FCC to address “threats to individual liberty posed by corporations that are abusing dominant positions in the market,” specifically “Big Tech and its attempts to drive diverse political viewpoints from the digital town square.” He called for more stringent transparency rules for social media platforms like Facebook and YouTube and “empower consumers to choose their own content filters and fact checkers, if any.” Carr and Ratcliffe would require Senate confirmation for their posts.

Saquon Barkley becomes ninth running back to rush for 2,000 yards in a season1. Nothing CMF Buds , which are equipped with HiFi sound, 42 db smart active noise cancellation, and retail for under $40. If other earbuds are not in your price range, these are a great alternative. Promising review: "As a producer and mixing engineer as well as generally a musician for many years, I can say these sound very good. Not too bassy, but not tinny or empty by any means. They charge super fast but also hold their charge for an unbelievable amount of time. I find they almost never fall out of my ears, and they feel super great." — Kaya Get it from Amazon for $27+ (available in four colors). 2. A Lexon Wireless Bluetooth Speaker that has a colorful retro design, perfect for any music lover. Promising review: "I wanted a small radio for my bathroom. This little number is very cool, the design is interesting, it really looks like a sculpture. However, the sound is decent! I use it for a local radio station, but you could also Bluetooth with it. I think for the price is a good deal if you want something unique!" — Gartia Get it from Amazon for $69.90 (available in 10 colors). 3. A Mikuna Protein Powder , which is plant-based and only contains five ingredients! This is great for the loved one who is working on their fitness journey in the New Year. It's keto, gluten-, and lectin-free. Promising review: "I’ve tried many vegan and whey-based proteins over the years, and by far, Mikuna’s chocho protein has been the most effective! Vegan protein powders are usually pea-based, which can easily cause bloating, gas, and very soft stool. Whey-based proteins are not as easily digestible and tend to be too watery or have other unnecessary ingredients to create the right texture." — Bobby Get it from Amazon for $35 (available in three flavors and four sizes). 4. A Vintage Casis Watch for someone who never knows what time it is and is always running late. Promising review: "Ha. This is a watch of contradictions. Cheap, yet well-made. Small, but noticeable. Old, but it feels so damn new. The watch performs flawlessly, and despite mentions of it being retro, it is slick, modern, and even better looking in person." — Customer Get it from Amazon for $19.99 (available in two colors). 5. An Adidas Handball Spezial Sneaker because they're both stylish and comfortable. Plus, they're great if they are trying to pick up a new active hobby, like pickleball. Promising review: "Good design, youthful and elegant for any occasion, 10 out of 10." — vry Get it from Nordstrom starting from $66+ (available in men's sizes 7–14 and 13 colors). 6. A Titanium Always Pan Pro equipped with nonstick technology that is made without PFAS. If your partner loves to cook, they will jump for joy when they unwrap this pan. Promising review: "Love my Always Pan Pro! The seasoning and prepping was a little bit of an effort. However, after taking my time and following the instructions, it has turned out to be an amazing addition to my cooking routine. So far I have been thoroughly amazed with the Titanium Always Pro Pan and its abilities. I look forward to testing it more and also be amazed by the results!" — Customer Get it from Our Place for $135 (originally $195; available in chrome and chrome/gold). 7. Elwood Organic Cotton Sweatpants for that casual person in your life. These pants look great for lounging and everyday wear. Promising review: "I never have bought or worn sweat bottoms casually. I got a pair as a gift, and I am really enjoying them. The color, the fit, and the texture are all incredible. Very cozy feeling and elegant looking. I am wearing them out with friends and even in the office." — SSJR88 Get it from Nordstrom for $75 (available in sizes XS–XXL and six colors). 8. Dr.Groot Scalp Revitalizing Solution they can use to exfoliate, cleanse, and moisturize their scalp. It also encourages hair growth and strengthening if they are someone who is worried about hair thinning. Promising review: "I love this set. Definitely will be purchasing it again. Scalp feels so clean. (I use it after I apply some oils for hair grow). Hair becomes very soft. I use it for my son to control scalp flake and for my daughter too — she has curly hair and it helps to detangle it." — Oksana Get it from Amazon for $30 . 9. A ShaktiMat Acupressure Mat to promote relaxation and help relieve stress. No one can be upset about a gift that will help them release some tension. Read more about acupressure and stress at Cleveland Clinic . Promising review: "The endorphins released from laying on this mat provide instant stress and anxiety relief... It hurts at first, but after 1-2 minutes, it starts to feel good. Also, kitty cat approved!" — Noah Get it from on Amazon for $84 (available in seven colors). 10. A HigherDOSE Red Light Therapy Face Mask for a skin enthusiast or someone who wants to up their skincare routine. And since you gave it to them, they can't get mad if you use it sometimes too! Visible LED devices only treat pimples, and results vary depending on the person: read more about how to use them at the American Academy of Dermatology . Promising review: "I've been getting more serious about my skincare as I get older, and honestly, investing in the right stuff has made a huge difference! 🙌 I used to have one of those portable LED wands, but it was such a hassle to use consistently. That’s when I switched to the HIGHERDOSE LED face mask, and wow — it’s a game-changer! It’s super easy to throw on for 10 minutes after I wash my face before bed. So relaxing, and my skin is already glowing ✨ after just a few weeks of using it regularly. I’m really excited to see the long-term results! If you’re thinking about stepping up your skincare routine, this is 100% worth it. 😊" — Jake Get it from Amazon for $279.20 . 11. A Stanley mug with a "big grip" handle to conveniently keep their morning coffee warm and their evening beverage cold. Promising review: "Built to last, it’s rugged, durable, and easy to clean. Whether you’re at a party, camping, or relaxing at home, this mug adds a fun, classic vibe to any setting. If you want a sturdy, no-nonsense beer stein, this one’s a winner." — DP Get it from Amazon for $25 (available in eight colors). 12. A Beast Blender Plus is perfect for making smoothies, dressings, and sauces. It also serves as a statement piece in their kitchen. Promising review: "I am SO happy I purchased this blender. Style is important to me, but so is functionality and this blender covers both points beautifully. I have a fruit smoothie with amino protein powder almost every morning, and this setup makes it so easy to blend and go. I’ve never had any issues with the blend power. I will typically throw in a cup of frozen mixed berries, frozen banana, a heaping scoop of my protein powder, and water, and it never seems to struggle, especially if I do the water first, as suggested. Absolutely worth every penny." — Ryan Get it from Amazon for $84.15+ (available in two sizes and five colors). 13. A Hawthorne Leather Cologne ideal for the scent enthusiast in your life. It is long-lasting and a fraction of the price of luxury colognes. Promising review: "Usually, when I buy cologne, it fades and gets a worse aroma over time. Not this one. The longer you wear this, the better the scent. Even when you sweat. The scent reminds me of the Harry Potter soap from Dr Squatch. It's definitely my favorite." — Dom Get it from Amazon for $50 . 14. A Soni Cozy Diffuser if they could use a little more fragrance in their space. Promising review: "I love the Seasons portable diffuser! Its compact size makes it easy to move around and place in different spots around my apartment. The sleek, minimalist design blends effortlessly with any decor, and the LED lighting adds a cozy touch. Overall, this diffuser is a perfect addition for creating a calm and inviting ambiance anywhere!" — A Get it from Bloomingdale's for $173.70 or from Seasons for $135 . 15. An Oura Ring — a wonderful gift that tracks their activity, heart rate, and sleep! Plus, it has a 5–7 day battery life. Promising review: "I’ve had the Oura ring for a month now and I love it so much! I had wanted this ring since it first came out but could never afford it. Now that you can use your FSA/HSA, it is possible. Since I used mine, I went with my favorite color rose gold. The color itself is gorgeous but not a true rose gold. It’s more of a true gold. Doesn’t matter because it’s beautiful and so functional. I look forward to waking up and checking my stats on the app. It is so accurate, too!" — Griselda Get it from Amazon for $249 (available in sizes 6–13 and seven colors). Some reviews have been edited for length and/or clarity.

Heartbroken family blames Walmart for 9-year-old's death after metal cart incident and years of seizuresPhoto: Shedeur Sanders Reveals Custom Giants Cleats for Colorado's Bowl Game vs. BYU

NCAA Field Hockey: Saint Joseph’s stuns UNC, will take on Northwestern for titleMLB Rumors: Pete Alonso Contract Interests Giants in Free Agency amid Mets Buzz